Enzymes of the sphingolipid metabolism as potential prognostic markers for breast cancer patients - and the impact of a anti-hormone therapy

分析雌激素受体阳性和阴性乳腺癌细胞经激素、SERM和SERD处理后鞘磷脂代谢酶，特别是神经酰胺合成酶的表达、蛋白水平和活性，从而确定其作为乳腺癌患者预后标志物的可能性。因此，导致这些酶在乳腺癌肿瘤中表达的激素依赖性改变的分子机制以及抗激素治疗对这些酶表达的影响还有待研究。此外，这些变化对乳腺癌细胞生长的影响以及鞘磷脂代谢的酶是否是乳腺癌肿瘤的潜在治疗靶点还有待分析。

Expression, protein level and activity of enzymes of the sphingolipid metabolism, especially ceramide synthases, after hormone, SERM and SERD treatment in estrogen receptor positive and negative breast cancer cells is to be analyzed and therefore the potential as prognostic marker of breast cancer patients is determined. Therefore molecular mechanisms, which lead to a hormone-dependent altered expression of these enzymes in breast cancer tumors and the impact of a anti-hormone therapy on the expression of these enzymes are to be investigated. Additionally, the impact of these alterations on the breast cancer cell growth and whether the enzymes of the sphingolipid metabolism are a potential therapeutic target in breast cancer tumors is to be analyzed.